MINNEAPOLIS, MN / ACCESSWIRE / February 16, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, announced financial results for the fourth quarter and year ended December 31, 2020 and summarized recent business progress.
“We built momentum in our business over the past few months, signing additional clinical trial agreements to collaborate with several major cancer research centers and pharmaceutical companies while advancing additional new CELsignia tests. In December, we announced a collaboration with Massachusetts General Hospital, UCLA, Vanderbilt, and Puma Biotechnology for a Phase II trial to evaluate the safety and efficacy of Puma’s drug, Nerlynx, and AstraZeneca’s drug, Faslodex,” said Brian Sullivan, Chairman and Chief Executive Officer of Celcuity.
“Last month, we announced another clinical trial collaboration, our fourth one, with Sarah Cannon Research Institute and Pfizer, Inc., for a Phase II trial that will evaluate the efficacy and safety of two Pfizer targeted therapies, VIZIMPRO®, a pan-HER inhibitor, and XALKORI®, a c-Met inhibitor. Both of these recent collaborations aim to address a significant unmet need for new treatment options for metastatic HER2- breast cancer patients whose disease progressed on prior therapies.
“Additional collaboration discussions with pharmaceutical companies also progressed despite the headwinds from COVID-19. We remain confident we will finalize new clinical trial collaborations in the first half of 2021. Finally, although our FACT-1 and FACT-2 trials were somewhat impacted by COVID-19 related delays in recent months, we still expect interim results from these trials in the latter half of 2021 or early 2022.”
Recent Highlights and Upcoming Milestones
Fourth Quarter and Fiscal Year 2020 Financial Results
Unless otherwise stated, all comparisons are for the fourth quarter and full year ended December 31, 2020, compared with the fourth quarter and full year ended December 31, 2019.
Total operating expenses were $2.55 million for the fourth quarter of 2020, compared to $1.90 million for the fourth quarter of 2019. Operating expenses for the fiscal year 2020 were $9.56 million, compared to $7.81 million for the fiscal year 2019.
Research and development (R&D) expenses were $2.11 million for the fourth quarter of 2020, compared to $1.50 million for the fourth quarter of 2019. R&D expenses for fiscal year 2020 were $7.68 million, compared to $6.27 million for fiscal year 2019. The approximately $1.41 million increase during fiscal year 2020, compared to fiscal year 2019, resulted primarily from a $1.15 million increase in compensation related expenses, including approximately $0.49 million of non-cash stock-based compensation expense. In addition, other research and development expenses increased $0.26 million due to clinical validation and laboratory studies, and operational and business development activities.
General and administrative (G&A) expenses were $0.44 million for the fourth quarter of 2020, compared to $0.40 million for the fourth quarter of 2019. G&A expenses for fiscal year 2020 were $1.87 million, compared to $1.53 million for fiscal year 2019. The approximately $0.34 million increase during fiscal year 2020, compared to fiscal year 2019, resulted primarily from a $0.28 million increase in compensation related expenses, including approximately $0.24 million of non-cash stock-based compensation. In addition, other general and administrative expenses increased $0.06 million primarily due to professional fees associated with being a public company.
Net loss for the fourth quarter of 2020 was $2.55 million, or $0.25 per share, compared to a net loss of $1.81 million, or $0.18 per share, for the fourth quarter of 2019. Net loss for fiscal year 2020 was $9.47 million, or $0.92 per share, compared to $7.36 million, or $0.72 per share, for fiscal year 2019. Non-GAAP adjusted net loss for the fourth quarter of 2020 was $2.12 million, or $0.21 per share, compared to non-GAAP adjusted net loss of $1.45 million, or $0.14 per share, for the fourth quarter of 2019. Non-GAAP adjusted net loss for fiscal year 2020 was $7.71 million, or $0.75 per share, compared to non-GAAP adjusted net loss of $6.32 million, or $0.62 per share, for fiscal year 2019. Non-GAAP adjusted net loss excludes stock-based compensation expense. Because this item has no impact on Celcuity’s cash position, management believes non-GAAP adjusted net loss better enables Celcuity to focus on cash used in operations. For a reconciliation of financial measures calculated in accordance with generally accepted accounting principles in the United States (GAAP) to non-GAAP financial measures, please see the financial tables at the end of this press release.
Net cash used in operating activities for the fourth quarter of 2020 was $2.11 million, compared to $1.70 million for the fourth quarter of 2019.
At December 31, 2020, Celcuity had cash and cash equivalents of $11.6 million, compared to cash and cash equivalents of $18.7 million at December 31, 2019.
Conference Call
Management will host a conference call at 4:30 PM Eastern Time today to discuss the results. Anyone interested in participating should dial 1-866-831-8616 and use passcode 92066. Participants are asked to dial in 5 to 10 minutes prior to the start of the call.
About Celcuity
Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity’s 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient’s cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN. Further information about Celcuity can be found at www.celcuity.com.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements.” In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends” or “continue,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward looking statements in this press release include, without limitation, expectations with respect to new clinical trial collaborations and the timing or outcomes of such collaborations, commercializing diagnostic tests, the use of cash, the discovery of additional cancer sub-types, the development of additional CELsignia tests, the uses and breadth of application of CELsignia tests, the outcome of the FACT-1, FACT-2, FACT-3, and FACT-4 clinical trials, clinical trial patient enrollment and timing of results, anticipated benefits that Celcuity’s tests may provide to pharmaceutical companies and to the clinical outcomes of cancer patients, and expectations regarding the impact that the COVID-19 pandemic and related economic effects will have on Celcuity’s business and results of operations. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Celcuity, which include, but are not limited to, the unknown impact of the COVID-19 pandemic on Celcuity’s business and those other risks set forth in the Risk Factors section in Celcuity’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission on February 16, 2021. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123
Westwicke ICR
Mike Cavanaugh
mike.cavanaugh@westwicke.com
(617) 877-9641
Celcuity Inc.
Balance Sheets
|
|
December 31, 2020 | December 31, 2019 | ||||||
|
|
||||||||
|
Assets
|
||||||||
|
Current Assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 11,637,911 | $ | 18,735,002 | ||||
|
Deposits
|
22,009 | 22,009 | ||||||
|
Deferred transaction costs
|
– | 28,743 | ||||||
|
Payroll tax receivable
|
190,000 | 190,000 | ||||||
|
Prepaid assets
|
317,040 | 274,600 | ||||||
|
Total current assets
|
12,166,960 | 19,250,354 | ||||||
|
|
||||||||
|
Property and equipment, net
|
558,876 | 833,463 | ||||||
|
Operating lease right-of-use assets
|
230,911 | 196,983 | ||||||
|
Total Assets
|
$ | 12,956,747 | $ | 20,280,800 | ||||
|
|
||||||||
|
Liabilities and Stockholders’ Equity:
|
||||||||
|
Current Liabilities:
|
||||||||
|
Accounts payable
|
$ | 217,377 | $ | 142,773 | ||||
|
Finance lease liabilities
|
5,810 | 5,769 | ||||||
|
Operating lease liabilities
|
187,518 | 178,466 | ||||||
|
Accrued expenses
|
774,612 | 584,319 | ||||||
|
Total current liabilities
|
1,185,317 | 911,327 | ||||||
|
Finance lease liabilities
|
8,299 | 14,109 | ||||||
|
Operating lease liabilities
|
60,861 | 57,793 | ||||||
|
Total Liabilities
|
1,254,477 | 983,229 | ||||||
|
Total Stockholders’ Equity
|
11,702,270 | 19,297,571 | ||||||
|
Total Liabilities and Stockholders’ Equity
|
$ | 12,956,747 | $ | 20,280,800 | ||||
Celcuity Inc.
Statement of Operations
|
|
Three Months Ended December 31, | Years Ended December 31, | ||||||||||||||
|
|
2020 | 2019 | 2020 | 2019 | ||||||||||||
|
|
||||||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
|
||||||||||||||||
|
Research and development
|
$ | 2,107,272 | $ | 1,497,023 | $ | 7,683,522 | $ | 6,269,308 | ||||||||
|
General and administrative
|
444,064 | 400,742 | 1,872,642 | 1,535,993 | ||||||||||||
|
Total operating expenses
|
2,551,336 | 1,897,765 | 9,556,164 | 7,805,301 | ||||||||||||
|
Loss from operations
|
(2,551,336) | (1,897,765) | (9,556,164) | (7,805,301) | ||||||||||||
|
|
||||||||||||||||
|
Other income (expense)
|
||||||||||||||||
|
Interest expense
|
(26) | (36) | (120) | (159) | ||||||||||||
|
Interest income
|
469 | 88,776 | 82,109 | 446,096 | ||||||||||||
|
Other income, net
|
443 | 88,740 | 81,989 | 445,937 | ||||||||||||
|
Net loss before income taxes
|
(2,550,893) | (1,809,025) | (9,474,175) | (7,359,364) | ||||||||||||
|
Income tax benefits
|
– | – | – | – | ||||||||||||
|
Net loss
|
$ | (2,550,893) | $ | (1,809,025) | $ | (9,474,175) | $ | (7,359,364) | ||||||||
|
|
||||||||||||||||
|
Net loss per share, basic and diluted
|
$ | (0.25) | $ | (0.18) | $ | (0.92) | $ | (0.72) | ||||||||
|
|
||||||||||||||||
|
Weighted average common shares outstanding, basic and diluted
|
10,279,535 | 10,251,555 | 10,266,884 | 10,226,041 | ||||||||||||
Cautionary Statement Regarding Non-GAAP Financial Measures
This press release contains references to non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Management believes these non-GAAP financial measures are useful supplemental measures for planning, monitoring, and evaluating operational performance as they exclude stock-based compensation expense from net loss and net loss per share. Management excludes this item because it does not impact Celcuity’s cash position, which management believes better enables Celcuity to focus on cash used in operations. However, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share are not recognized measures under GAAP and do not have a standardized meaning prescribed by GAAP. As a result, management’s method of calculating non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may differ materially from the method used by other companies. Therefore, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may not be comparable to similarly titled measures presented by other companies. Investors are cautioned that non-GAAP adjusted net loss and non-GAAP adjusted net loss per share should not be construed as alternatives to net loss, net loss per share or other statements of operations data (which are determined in accordance with GAAP) as an indicator of Celcuity’s performance or as a measure of liquidity and cash flows.
Celcuity Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and
GAAP Net Loss Per Share to Non-GAAP Adjusted Net Loss Per Share
|
|
Three Months Ended December 31, |
Years Ended December 31, |
||||||||||||||
|
|
2020 | 2019 | 2020 | 2019 | ||||||||||||
|
|
||||||||||||||||
|
GAAP net loss
|
$ | (2,550,893) | $ | (1,809,025) | $ | (9,474,175) | $ | (7,359,364) | ||||||||
|
Adjustments:
|
||||||||||||||||
|
Stock-based compensation
|
||||||||||||||||
|
Research and development (1)
|
241,996 | 202,403 | 1,055,094 | 567,305 | ||||||||||||
|
General and administrative (2)
|
185,094 | 158,452 | 708,785 | 473,684 | ||||||||||||
|
Non-GAAP adjusted net loss
|
$ | (2,123,803) | $ | (1,448,170) | $ | (7,710,296) | $ | (6,318,375) | ||||||||
|
|
||||||||||||||||
|
|
||||||||||||||||
|
GAAP net loss per share – basic and diluted
|
$ | (0.25) | $ | (0.18) | $ | (0.92) | $ | (0.72) | ||||||||
|
Adjustment to net loss (as detailed above)
|
0.04 | 0.04 | 0.17 | 0.10 | ||||||||||||
|
Non-GAAP adjusted net loss per share
|
$ | (0.21) | $ | (0.14) | $ | (0.75) | $ | (0.62) | ||||||||
|
|
||||||||||||||||
|
Weighted average common shares outstanding, basic and diluted
|
10,279,535 | 10,251,555 | 10,266,884 | 10,226,041 | ||||||||||||
(1) Reflects a non-cash charge to operating expense for Research and Development stock-based compensation.
(2) Reflects a non-cash charge to operating expense for General and Administrative stock-based
SOURCE: Celcuity Inc.
View source version on accesswire.com:
https://www.accesswire.com/630020/Celcuity-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-and-Recent-Business-Highlights
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader…
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting…
MINNEAPOLIS, June 21, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the…
Shrivers Hospice sets a benchmark for quality care in Ohio with prestigious award LOS ANGELES,…